Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Where Great Emphasis is Put on Research.

IMBA: Prevention of hereditary breast cancer is possible

(c) IMBA © IMBA

In 2010, a group of researchers at the Institute for Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences in Vienna already discovered that the sex hormones can trigger breast cancer through two proteins of bone metabolism called "RANK" and "RANKL".

RANK inhibition protected mice against preliminary stages of cancer

The young scientist Verena Sigl now made the discovery that RANKL is also the main driver of genetically caused mammary cancer due to the mutated BRCA1 gene. In her study, the researcher compared mice with a mutation of the BRCA1 gene. First and foremost, RANK/RANKL were active. Carcinomas and extreme malignant changes, the preliminary stages of the carcinomas, developed in the breast. However, in those cases in which RANK was genetically inhibited, carcinomas were not found in a single mouse, and malignant changes took place much less frequently. 

In order to determine the relevance of their results for human beings, the scientists in Vienna along with researchers at the Medical University of Vienna and researchers from Toronto isolated breast tissue cells from women who had undergone preventive mastectomy because of their BRCAI mutation. After RANK was inhibited, a significant reduction of growth and spreading of breast tissue cells was observed in the human cell culture. This observation confirmed the enormous potential of an anti-RANK treatment in preventing cancer in human beings.

Preventive intake of drugs could prevent amputations

"Our finding is so exciting because there is already an approved drug on the market against RANKL, called Denosumab. It is an antibody with very few side effects, which binds tightly to RANKL and thus inhibits its ability to act”, said Verena Sigl. At present, the drug is prescribed for treating bone metastases and osteoporosis. Following the discovery made by Ms. Digl, it could be used for breast cancer prevention in the case of BRCA1 mutation carriers. From this vantage point, serious interventions such as breast amputations could be avoided.

The present work is the result of international collaboration. Scientists from Austria (IMBA, Vienna General Hospital) participated as well as researchers from Baltimore, Toronto, Canada and Barcelona.

Service: The research collaboration on the Internet: http://apps.ccge.medschl.cam.ac.uk/consortia/cimba/

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • 4. Mittelstandsforum Nordrhein-Westfalen

    18.06.2019, Dusseldorf, Germany

  • Expand to Austria

    26.06.2019, Brescia, Italy

Austria Map

Find the perfect location for your company

As a gaming machine and gaming software company, we particularly profit from the high level of education and innovative strength of Austria as a business location. We also value the strong loyalty and commitment of our local employees.

IGT Austria GmbH

igt
More testimonials

news from the business location Austria

A.T. Kearney: Austria improves in the investment ranking

The inflows related to foreign direct investments in Europe in 2018 fell by 73 percent to USD 100 billion from the prior-year level of USD 372 billion.

Innovations from Austria for the Logistics Sector

At the present time there are many influencing factors which pose challenges to the supply chain and logistics management. Solutions in this area are frequently developed by startups, also from Austria. Several of them will present their innovations at the Austrian Logistics Day and Logistics Future Lab.

More news All blog posts